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GAFCHROMIC film (EBT3) measurements in anthropomorphic 
phantoms. 
Results: Comparing data both via gamma analysis method 
(3%, 3mm) and DVH comparison (between TPS and MC), a 
very good agreement between dose distributions estimated 
by MC, TPS and films was shown. In table are summarized the 
gamma analysis results.  
 
 
The main differences between MC and TPS were detected in 
high and low density structures (bone and air cavities) where 
differences between dose to medium and dose to water (as it 
is computed by TPS) are highlighted. In a single plan, where 
the PTV included bone structures (CTV was contoured in soft 
tissue), a 3mm displacement along axial, coronal and sagittal 
direction was simulated. In figure DVHs before and after the 
shift are shown.  
 
It is clear that the CTV coverage is not affected and the 
homogeneity in the CTV is guaranteed even if a lower than 
prescribed dose to medium was detected in the bone of the 
reference dose distribution. 
Conclusions: This work proposes a method to model in TOPAS 
a proton therapy PBS machine using commissioning 
measurements with no machine geometrical head 
description. This modeling lets the user to simulate a 
complete treatment plan having as the only input the DICOM 
file produced by the TPS. This gives the physicist a 
completely independent MC dose calculation algorithm. One 
of the most interesting features is that the dose distribution 
is given in terms of absolute dose and the comparison can be 
implemented with no dose-rescaling. It can be used to 
validate the dose distribution coming from TPS or, in a near 
future, as a patient-specific QA tool. 
[1] Perl J et al. TOPAS - An innovative proton Monte Carlo 
platform for research and clinical applications. Med Phys. 
2012;39(6818-6837). 
[2] Soukup M. et al. A pencil beam algorithm for intensity 
modulated proton therapy derived from Monte Carlo 
simulations. Phys. Med. Biol. 50 (2005) 5089–5104. 
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Purpose/Objective: In proton therapy protons are used to 
deliver radiation to a target. This promises higher dose 
conformality in comparison with regular radiotherapy 
techniques. Intensity Modulated Proton Therapy (IMPT) is a 
form of proton therapy, in which a pencil beam is used to 
cover the target. Because image guidance has an increasing 
role in radiotherapy and MRI is a prime candidate for this 
imaging, the dosimetric feasibility of IMPT in a magnetic field 
of 1.5 T and the effect on the generated dose distributions 
compared to those at 0 T is evaluated, using Monte Carlo 
simulations. 
Materials and Methods: To generate the IMPT plans, existing 
treatment planning software for the MR Linac was used with 
proton beamlets as input. Using the Monte Carlo software 
TOol for PArticle Simulation (TOPAS), proton beamlets were 
generated. First the interactions within a box of water were 
simulated, in order to analyze the shape of the Bragg Peak 
inside a 1.5 T magnetic field, compared to the one without a 
magnetic field. Next, three different sites were selected to 
generate IMPT plans for, based on DICOM data. The selected 
sites were a shallow and deep head-neck tumor and an 
artificial liver tumor. As input for the plans, beamlets from 
three intuitively selected gantry angles were generated, 
covering the target completely from every angle, both in a 0 
T and 1.5T magnetic field. The generation of the plans was 
accomplished using dedicated, homemade software, based on 
an inverse optimization method. For all sites, the IMPT plans 
for a 0 T and a 1.5 T magnetic field were generated and 
analyzed, by comparison of the dose parameters and 
difference inside the target. 
Results: For a simulated 150 MeV proton beam in a water 
phantom, the shift of the Bragg Peak due to the magnetic 
field was 1.14 cm, which is in accordance to the analytical 
solution. A Gaussian fit for the lateral dose profile at the 
Bragg Peak gave σ = 0.36 cm both without and with a 
magnetic field. For the DICOM data, the dose distributions of 
the generated IMPT plans for two sites are shown in figures 
1a and 1b and figures 1d and 1e. The mean dose difference is 
μ = -8.5 × 10-3 Gy (σ = 0.14 Gy) for the shallow head-neck 
target, μ = -0.17 Gy (σ = 1.11 Gy) for the deep head-neck 
target (figure 1c) and μ = -0.34 Gy (σ = 0.62 Gy) for the liver 
target (figure 1f). The DVHs of the target were similar and 




Conclusions: This study shows that the generation of an IMPT 
plan in a magnetic field is feasible. The impact of the 
magnetic field is only on the curvature of the proton beam, 
which should be taken into account, but the resulting dose 
distributions are equivalent. It also shows that the introduced 
framework, which consists of Monte Carlo simulation 
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combined with the use of an inverse optimization method, 
can be used to generate IMPT plans. These plans can be used 
in future dosimetric comparisons with IMRT, the MR Linac and 
conventional IMPT. Finally, it shows the dosimetric feasibility 
of IMPT in a 1.5 T magnetic field.  
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Purpose/Objective: To compare the clinical benefit of robust 
optimized Intensity Modulated Proton Therapy (IMPT) with 
current photon radiotherapy (IMRT) and PTV-based IMPT for 
head and neck cancer (HNC) patients. The clinical benefit is 
quantified in terms of both Normal Tissue Complication 
Probability (NTCP) and target coverage in the case of setup 
and range errors. 
Materials and Methods: For 10 HNC patients, PTV-based IMRT 
(7 fields), robust optimized (minimax) and PTV-based IMPT 
(2, 3, 4, 5 and 7 fields) plans were tested on robustness, 
meaning that at least 98% of the CTVs had to receive ≥ 95% of 
the prescribed dose in 90% of the possible systematic setup 
and range error scenarios. Robust optimized plans differed 
from PTV-based plans in that they target the CTV and 
penalize possible error scenarios, instead of using the static 
isotropic CTV-PTV margin. Perturbed dose distributions of all 
plans were acquired by simulating in total 8060 setup (+/- 
2.5mm) and range error (+/-3%) combinations. Furthermore, 
NTCP models for xerostomia and dysphagia were used to 
estimate the clinical benefit of IMPT versus IMRT.  
Results: The robustness criterion was met in the IMRT and 
minimax IMPT plans in all error scenarios, but for PTV-based 
IMPT plans this was only the case in 4 out of 10 patients. The 
volumes receiving deficient dose were sometimes centrally 
situated in the CTV (Figure), indicating that expansion of the 
CTV-PTV margin would not solve the underdosage. Mean 
doses to the major salivary glands and swallowing related 
organs at risk (OAR) were generally lower with minimax than 
with PTV-based IMPT. Xerostomia and dysphagia NTCP values 
calculated for IMRT plans were reduced by 16.4% (95% CI; 
10.1-22.7%) and 9.9% (95% CI; 4.9-14.9%) with minimax IMPT 
in the 5 patients with the largest NTCP reductions. In the 
other 5 patients the average NTCP reduction was smaller 
(xerostomia: 4.7% (95% CI; 1.0-8.3%) ; dysphagia: 3.0% (95% 
CI; -0.2-6.2%). Increasing the number of fields did not 
contribute to plan robustness, but improved organ sparing. 
Conclusions: The clinical benefit in terms of NTCP of robust 
optimized (minimax) IMPT compared to IMRT is equal or even 
greater than that of PTV-based IMPT in head and neck 
patients. Furthermore, the target coverage of minimax IMPT 
plans in the presence of setup and range errors was 
comparable to that of current photon radiotherapy (IMRT) 
plans.
 
Figure. Dose distributions of IMRT (a,d), PTV-based IMPT (b,e) 
and minimax optimized IMPT plans (c,f) in nominal (a-c) and 
an error scenario (d-f) with a setup error of 
x=0.18;y=0;z=0.18cm and a range error of 3%. Both CTV70 
(blue lines) and CTV54.25 (black lines) are shown in all dose 
distributions.  
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Purpose/Objective: To investigate the accuracy of dose 
calculation on cone beam CT (CBCT) data sets after HU-RED 
calibration and validation in phantom studies and clinical 
patients. 
Materials and Methods: Calibration of HU-RED curves for kV-
CBCT were generated for three clinical protocols (H&N, 
thorax and pelvis) using a Gammex RMI phantom ® (Gammex 
RMI, Middleton, WI) with human tissue equivalent inserts and 
additional perspex blocks to account for patient scatter. Two 
calibration curves per clinical protocol were defined, one for 
the Varian Truebeam 2.0 and another for the OBI systems 
(Varian Medical Systems Inc., Palo Alto, USA). Differences in 
HU values with respect to the CT-calibration curve were 
evaluated for all the inserts. 
Four radiotherapy plans (breast, prostate, H&N and lung) 
were produced on an anthropomorphic phantom (Alderson) to 
evaluate dose differences on the kV-CBCT with the new 
calibration curves with respect to the CT based dose 
calculation. Dose calculation was performed in Eclipse TPS 
using an anisotropic analytic dose calculation algorithm (AAA, 
Varian Medical Systems Inc.). Dose differences were 
evaluated according to the D2%, D98% and Dmean metrics 
extracted from the DVHs of the plans and g- evaluation (2%, 
1mm) on the three planes at the isocenter for all plans. 
Clinical evaluation was performed on ten patients and dose 
differences were evaluated as in the phantom study. 
Results: HU values on the kV-CBCT calibration curves 
exhibited deviations with respect to the CT-calibration curve 
on the low- (lung) and high-density (bone) inserts. These 
deviations were found to be ca. 250 HU. Differences between 
the Truebeam 2.0 and OBI-system for HU-RED curve were 
ca.14 %. Radiotherapy plans calculated on the 
anthropomorphic phantom showed very good agreement with 
the CT-based calculated plans (Table 1, Figure 1).  
